CD163 and prostate neoplasm: By quantifying VSIG4 fluorescence on 120 cores from 10 different tumor types, VSIG4 was found to be specifically expressed on a subset of CD163+ macrophages to varying degrees across most cores (75% or more) in lung, melanoma, kidney, head and neck, colorectal, ovarian, and pancreatic tumors and in a smaller fraction of cores in breast, bladder, and prostate tumors (Supplementary Figure S3D).